Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan 6;12(2):465.
doi: 10.3390/jcm12020465.

Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment

Kosei Takagi  1 , Yuzo Umeda  1 , Ryuichi Yoshida  1 , Tomokazu Fuji  1 , Kazuya Yasui  1 , Takahito Yagi  1 , Toshiyoshi Fujiwara  1
Affiliations
Editorial

Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment

Kosei Takagi et al. J Clin Med. .

Abstract

The incidence and mortality rates of pancreatic ductal adenocarcinoma (PDAC) have increased in recent years worldwide [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Grossberg A.J., Chu L.C., Deig C.R., Fishman E.K., Hwang W.L., Maitra A., Marks D.L., Mehta A., Nabavizadeh N., Simeone D.M., et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J. Clin. 2020;70:375–403. doi: 10.3322/caac.21626. - DOI - PMC - PubMed
    1. Hu J.X., Zhao C.F., Chen W.B., Liu Q.C., Li Q.W., Lin Y.Y., Gao F. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J. Gastroenterol. 2021;27:4298–4321. doi: 10.3748/wjg.v27.i27.4298. - DOI - PMC - PubMed
    1. Burris H.A., 3rd, Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J. Clin. Oncol. 1997;15:2403–2413. doi: 10.1200/JCO.1997.15.6.2403. - DOI - PubMed
    1. Oettle H., Neuhaus P., Hochhaus A., Hartmann J.T., Gellert K., Ridwelski K., Niedergethmann M., Zülke C., Fahlke J., Arning M.B., et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial. JAMA. 2013;310:1473–1481. doi: 10.1001/jama.2013.279201. - DOI - PubMed

Publication types

LinkOut - more resources